KEYNOTE-006-Studie: 4-Jahres-Überleben und Ergebnisse nach Absetzen von Pembrolizumab (Pembro) nach zwei Jahren bei Patienten mit Ipilimumab-naivem fortgeschrittenen Melanom

ASCO Annual Meeting 2018 – Abstract: No. 9503, Long, GV et al.: KEYNOTE-006-Studie

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

 

Conclusion:

“Pembro provides durable antitumor activity in treatment-naive or -experienced pts with advanced melanoma. Of pts who completed 2 y pembro, 86% were progression free at 20 mo. Pembro is safe and provides additional antitumor activity as second-course treatment.”

 

Clinical trial information: NCT01866319

 

Quelle:
Long, GV et al. ASCO 2018, Oral Abstract Session

J Clin Oncol 36, 2018 (suppl; abstr 9503)

https://meetinglibrary.asco.org/record/159075/abstract